Cargando…
Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants
BACKGROUND: Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA). OBJECTIVES: Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey‐protein formula (eHWF) in CMA children were assess...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542408/ https://www.ncbi.nlm.nih.gov/pubmed/35754130 http://dx.doi.org/10.1111/pai.13814 |
_version_ | 1784804142723629056 |
---|---|
author | Dahdah, Lamia Roelofs, Mieke Knipping, Karen de Vries, Esther Rijnierse, Anneke Garssen, Johan Brand, Paul L. P. Fiocchi, Alessandro |
author_facet | Dahdah, Lamia Roelofs, Mieke Knipping, Karen de Vries, Esther Rijnierse, Anneke Garssen, Johan Brand, Paul L. P. Fiocchi, Alessandro |
author_sort | Dahdah, Lamia |
collection | PubMed |
description | BACKGROUND: Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA). OBJECTIVES: Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey‐protein formula (eHWF) in CMA children were assessed. METHODS: In this prospective, randomized, international, multi‐center study (Trial NL3889), 34 children with confirmed CMA (74% IgE‐mediated) underwent a double‐blind, placebo‐controlled food challenge (DBPCFC) with an eHWF developed with non‐porcine enzymes, supplemented with prebiotic short‐chain galacto‐ and long‐chain fructo‐oligosaccharides (0.8 g/L, ratio 9:1), arachidonic acid (0.35/100 g), and docosahexaenoic acid (0.35/100 g). If tolerant to the eHWF, children participated in a 7‐day open food challenge with this eHWF. Anthropometrics and GI tolerability were assessed in an optional 16‐weeks follow‐up. RESULTS: Of the 34 children who started the DBPCFC with the eHWF, 25 subjects (19 boys, mean age: 61 weeks, 18 with IgE‐mediated CMA) completed the DBPCFC and 7‐day open challenge without major protocol deviations and tested negative at both challenges. One child experienced a late moderate eczematous allergic reaction in the optional follow‐up period, indicating the need for close monitoring of subjects starting new formula. Weight and length gain followed the World Health Organization growth curves. Changes in frequency and consistency of stools upon test formula intake were transient. CONCLUSIONS: The newly developed eHWF is a suitable option in CMA treatment as all subjects tolerated the product. This result is in line with the international criteria for hypoallergenicity (American Academy of Pediatrics) that state that more than 90% of CMA children must tolerate the formula. Use of the formula is also associated with normal growth curves and GI tolerability. TRIAL REGISTRATION: Trial NL3889, https://www.trialregister.nl/trial/3889. |
format | Online Article Text |
id | pubmed-9542408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95424082022-10-14 Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants Dahdah, Lamia Roelofs, Mieke Knipping, Karen de Vries, Esther Rijnierse, Anneke Garssen, Johan Brand, Paul L. P. Fiocchi, Alessandro Pediatr Allergy Immunol Original Articles BACKGROUND: Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA). OBJECTIVES: Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey‐protein formula (eHWF) in CMA children were assessed. METHODS: In this prospective, randomized, international, multi‐center study (Trial NL3889), 34 children with confirmed CMA (74% IgE‐mediated) underwent a double‐blind, placebo‐controlled food challenge (DBPCFC) with an eHWF developed with non‐porcine enzymes, supplemented with prebiotic short‐chain galacto‐ and long‐chain fructo‐oligosaccharides (0.8 g/L, ratio 9:1), arachidonic acid (0.35/100 g), and docosahexaenoic acid (0.35/100 g). If tolerant to the eHWF, children participated in a 7‐day open food challenge with this eHWF. Anthropometrics and GI tolerability were assessed in an optional 16‐weeks follow‐up. RESULTS: Of the 34 children who started the DBPCFC with the eHWF, 25 subjects (19 boys, mean age: 61 weeks, 18 with IgE‐mediated CMA) completed the DBPCFC and 7‐day open challenge without major protocol deviations and tested negative at both challenges. One child experienced a late moderate eczematous allergic reaction in the optional follow‐up period, indicating the need for close monitoring of subjects starting new formula. Weight and length gain followed the World Health Organization growth curves. Changes in frequency and consistency of stools upon test formula intake were transient. CONCLUSIONS: The newly developed eHWF is a suitable option in CMA treatment as all subjects tolerated the product. This result is in line with the international criteria for hypoallergenicity (American Academy of Pediatrics) that state that more than 90% of CMA children must tolerate the formula. Use of the formula is also associated with normal growth curves and GI tolerability. TRIAL REGISTRATION: Trial NL3889, https://www.trialregister.nl/trial/3889. John Wiley and Sons Inc. 2022-06-14 2022-06 /pmc/articles/PMC9542408/ /pubmed/35754130 http://dx.doi.org/10.1111/pai.13814 Text en © 2022 Nutricia Research B.V. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Dahdah, Lamia Roelofs, Mieke Knipping, Karen de Vries, Esther Rijnierse, Anneke Garssen, Johan Brand, Paul L. P. Fiocchi, Alessandro Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants |
title | Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants |
title_full | Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants |
title_fullStr | Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants |
title_full_unstemmed | Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants |
title_short | Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants |
title_sort | hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542408/ https://www.ncbi.nlm.nih.gov/pubmed/35754130 http://dx.doi.org/10.1111/pai.13814 |
work_keys_str_mv | AT dahdahlamia hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants AT roelofsmieke hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants AT knippingkaren hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants AT devriesesther hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants AT rijnierseanneke hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants AT garssenjohan hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants AT brandpaullp hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants AT fiocchialessandro hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants |